Literature DB >> 30896269

Klotho, vitamin D and homocysteine levels during acute episode and remission periods in schizophrenia patients.

Esra Yazici1, Tugba Mutu Pek1, Derya Guzel1, Ahmet Bulent Yazici1, Ozlem Akcay Ciner1, Atila Erol1.   

Abstract

AIM: Neurodegenerative processes are effective in schizophrenia. However, the underlying causes of the symptoms and associated factors have not yet been fully elucidated. Recent research has focused on the relationship between neurodegeneration and vitamin D, Klotho and homocysteine levels. In this study, we aimed to investigate this relationship in schizophrenia.
METHOD: This study included 30 schizophrenic inpatients, 30 schizophrenic outpatients in remission and 28 healthy volunteers as the control group. The psychiatric diagnoses of our patients were evaluated according to DSM-IV criteria. The Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF) scale and the Clinical Global Impression (CGI) scale were used for clinical measurements. Serum Klotho, homocysteine, vitamin D, vitamin B12 and folic acid levels were analyzed using ELISA and compared with clinical properties.
RESULTS: The PANSS scores and CGI scores were higher in schizophrenic inpatients than outpatients, and the GAF scores were lower (p < 0.05). Three groups were compared for Klotho, homocysteine and vitamin D serum levels; Klotho levels were elevated but the difference was not statistically significant (p > 0.05). However, vitamin B12, folic acid and homocysteine levels were higher in schizophrenic patients than the control group (p < 0.05).
CONCLUSIONS: Higher levels of homocysteine with concomitant higher levels of vitamin B12 and folic acid suggest a relationship of this pathway with schizophrenia. Differences in Klotho levels were elevated but it was not significant. Replication studies to investigate probable associations with larger samples are needed.

Entities:  

Keywords:  Klotho; Schizophrenia; aging; biomarker; homocysteine; vitamin D

Mesh:

Substances:

Year:  2019        PMID: 30896269     DOI: 10.1080/08039488.2019.1582697

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  6 in total

1.  Klotho, BDNF, NGF, GDNF Levels and Related Factors in Withdrawal Period in Chronic Cannabinoid Users.

Authors:  Ahmet Bulent Yazici; Derya Guzel; Elif Merve Kurt; Betul Turkmen; Esra Yazici
Journal:  Indian J Clin Biochem       Date:  2021-02-08

2.  Increased Plasma Level of Longevity Protein Klotho as a Potential Indicator of Cognitive Function Preservation in Patients With Schizophrenia.

Authors:  Jian-Wen Xiong; Jin-Qiong Zhan; Tao Luo; Hai-Bo Chen; Qi-Gen Wan; Yan Wang; Bo Wei; Yuan-Jian Yang
Journal:  Front Neurosci       Date:  2020-06-16       Impact factor: 4.677

3.  Association between plasma homocysteine levels and cognitive deficits in Han Chinese patients with schizophrenia across age groups.

Authors:  Sumiao Zhou; Yuanyuan Huang; Yangdong Feng; Hehua Li; Kai Wu; Mingzhe Yang; Fengchun Wu; Xingbing Huang
Journal:  Sci Rep       Date:  2021-10-05       Impact factor: 4.379

4.  BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia.

Authors:  Betul Aslan Turkmen; Esra Yazici; Derya Guzel Erdogan; Mehmet Akif Suda; Ahmet Bulent Yazici
Journal:  BMC Psychiatry       Date:  2021-11-11       Impact factor: 3.630

5.  The Effects of Plasma Homocysteine Level on the Risk of Three Major Psychiatric Disorders: A Mendelian Randomization Study.

Authors:  Jing Yu; Ranran Xue; Qiuling Wang; Hao Yu; Xia Liu
Journal:  Front Psychiatry       Date:  2022-03-21       Impact factor: 4.157

Review 6.  Nicotinamide N-Methyltransferase: Genomic Connection to Disease.

Authors:  David B Ramsden; Rosemary H Waring; Richard B Parsons; David J Barlow; Adrian C Williams
Journal:  Int J Tryptophan Res       Date:  2020-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.